4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-20-034138
Chief Executive Officer sold 17,275 shares at an average $64.68 ($1,117,266)
- Chief Executive Officer gave up 779 shares (to pay taxes)
- Chief Executive Officer acquired 17,275 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2020-06-01 | Option exercise | +17,275 | $1.81 | $31,268 | 188,801 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-06-01 | Sale | −2,400 | $63.57 | $152,568 | 186,401 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-06-01 | Sale | −9,300 | $64.61 | $600,873 | 177,101 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-06-01 | Sale | −5,575 | $65.26 | $363,825 | 171,526 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-06-02 | Shares withheld for taxes | −779 | $66.26 | $51,617 | 170,747 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2020-06-01 | Option exercise · Stock Option (Right to Buy) | −17,275 | 162,783 | D | ||
| Open-market sales · 17,275 sh · avg $64.68 · $1,117,266 | |||||||
Loading xslF345X03/doc4.xml…